- Valdoxan is an antidepressant manufactured by Servier.
- The Association of the British Pharmaceutical Industry (ABPI) says that Servier breached Clause 2 of the Prescription Medicines Code of Practice because the company did not release new data within an “internationally agreed timeframe.”
- The breach was discovered after a private citizen made an official complaint to the authorities.
Servier is not appealing the decision by the ABPI, which considers the company “in breach” of several key codes, including Clause 2, “bringing discredit upon and reducing confidence in the pharmaceutical industry.”
The company was also ruled in breach of two additional clauses, including “failing to maintain high standards” and “failing to meet the required timeframe in which to disclose details of clinical trials.” The studies in question were published between 2008 and 2011.